NASDAQ$SPRY
ARS Pharmaceuticals Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
ARS Pharmaceuticals experienced a transformative quarter with FDA approval of Neffy in the U.S. and European Commission approval of EURneffy in the EU, along with commercial launch underway and a licensing agreement with ALK-Abelló.
ARS Pharmaceuticals reported a net loss of $19.1 million for Q3 2024. Total revenue was $2.1 million, including $0.6 million in net product revenue from Neffy sales and $1.5 million in collaboration revenue. The company's cash position was strong with $349.6 million on a pro forma basis, adjusted for the $145 million upfront payment from ALK-Abelló.
- Commercial launch of neffy underway in the United States.
- Supplemental NDA for neffy 1mg dose granted priority review by FDA with a PDUFA target date of March 6, 2025.
- Exclusive license agreement with ALK-Abelló to commercialize neffy in Europe, Canada and certain other geographies for $145 million upfront and up to $465 million total with double-digit royalties.
- Company is well-capitalized with $349.6 million in cash, cash equivalents and short-term investments on a pro forma basis.
Headline financials
Revenue & EPS history
ARS Pharmaceuticals · Revenue · Quarterly
$2.07M
Revenue by segment
ARS Pharmaceuticals · $22.7M total across 3 segments · Q1 2026
- Product revenue, net$17.5M—76.9%
- Revenue under supply agreements$2.74M—12.1%
- Revenue under collaboration agreements$2.49M—11.0%
Forward guidance
ARS Pharmaceuticals expects its capital to be sufficient to fund its current operating plan for at least three years. Initial coverage decisions from key payors are expected by year-end.
Tailwinds
- Ongoing U.S. commercial launch of neffy.
- Priority review granted for supplemental NDA for neffy 1mg dose.
- PDUFA target date set for March 6, 2025.
- Exclusive licensing agreement with ALK-Abelló for commercialization of neffy in Europe, Canada, and other geographies.
- Regulatory submissions expected in China, Japan, United Kingdom and Canada.
Headwinds
- Potential safety and other complications from neffy.
- Potential for payors to delay, limit or deny coverage for neffy.
- Market acceptance of neffy vis-à-vis intramuscular injectable products.
- Impact of government laws and regulations.
- PDUFA target action date may be delayed due to various factors outside ARS Pharmaceuticals’ control.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
-1.2%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+2.4%
Avg return
30 days after
41%
9 / 22 earnings
Positive
+22.8%
Q4 2024
Best reaction
-15.1%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -6.2% | -1.5% | +23.1% | |
| Q4 2025 | -0.1% | -7.4% | -9.6% | |
| Q3 2025 | +0.8% | -7.2% | +18.0% | |
| Q2 2025 | -5.2% | -15.8% | -39.8% | |
| Q1 2025 | -9.4% | +6.8% | +15.3% | |
| Q4 2024 | +22.8% | +12.9% | +27.7% | |
| Q3 2024 | -15.1% | -17.0% | -28.4% | |
| Q2 2024 | +2.7% | +16.7% | +26.1% | |
| Q1 2024 | -3.5% | -0.9% | -2.8% | |
| Q4 2023 | -0.6% | +14.9% | -2.6% | |
| Q3 2023 | +4.2% | +18.2% | +48.6% | |
| Q2 2023 | -0.9% | +2.2% | +7.0% | |
| Q1 2023 | +1.6% | +6.6% | -23.6% | |
| Q4 2022 | -5.0% | -17.0% | -18.1% | |
| Q3 2022 | -1.5% | -5.5% | +13.5% | |
| Q2 2022 | +1.0% | +7.2% | +3.2% | |
| Q4 2021 | -8.8% | +11.7% | +44.1% | |
| Q1 2022 | -8.8% | -4.5% | -11.6% | |
| Q3 2021 | +0.2% | +3.5% | -17.1% | |
| Q2 2021 | +2.6% | -1.0% | -4.0% | |
| Q1 2021 | +9.1% | +3.2% | -21.0% | |
| Q4 2020 | -5.9% | -9.6% | +4.5% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro